drugset / Trial / NCT03583086
Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors
Phase 1/2
Completed
88 enrolled
Vanderbilt-Ingram Cancer Center
Bristol-Myers Squibb · collabXcovery Holdings, Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a two-agent, open-label, non-randomized, Phase 1/2 dose escalation and dose expansion study of combinatorial oral vorolanib plus infusional nivolumab in patients with Non-Small Cell Lung Cancer naïve to checkpoint inhibitor therapy, Non-Small Cell Lung Cancer who have progressed on checkpoint inhibitor therapy, Small Cell Lung Cancer ( who have progressed on platinum-based chemotherapy, and thymic carcinoma.
Timeline
- Start
- 2018-07-10
- Primary completion
- 2024-02-21
- Completion
- 2024-04-27